Posted by Michael Wonder on 18 Jan 2018
Early benefit assessments: the 220th dossier evaluation completed at the turn of the year
18 January 2018 - Oncology remains by far the most common indication.
In the course of 2017, the IQWiG completed its 200th dossier assessment: At the turn of the year, the results of the 216th to 220th early benefit assessment were published. A comparison of the indication areas shows that oncology is well ahead in terms of both the number of active substances tested and the proportion of active substances with at least one hint of added benefit. Particularly low is the proportion with attested added benefit in psychiatric and neurological diseases.
The Joint Federal Committee (G-BA) comes to about 30% of the dossier ratings to a different conclusion than the IQWiG. The G-BA's judgment is about as often better and worse than the Institute's assessment - mainly due to new findings from the comments on the IQWiG assessments.
